CHF 26.4 million (EUR 28.4 million) extension, led by existing investors, accelerates clinical development of NU101 and NU201 radiotheranostic programs in metastatic castration resistant prostate cancer and metastatic breast cancer Basel, Switzerland / Munich, Germany, May 27, 2026 – NUCLIDIUM AG, a clinical-stage radiopharmaceutical company, today announced the closing of an oversubscribed CHF 26 million (EUR 28.4 million) Series B extension, bringing the Series B total raised to CHF 105 million (approxima ...